UK markets close in 8 hours 13 minutes

Atossa Genetics Inc. (YAG2.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.9630+0.0010 (+0.10%)
As of 08:14AM CEST. Market open.
Full screen
Previous close0.9620
Open0.9630
Bid0.9630 x 0
Ask1.0300 x 0
Day's range0.9630 - 0.9630
52-week range0.5770 - 2.1350
Volume1,000
Avg. volume2,159
Market cap127.571M
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Atossa Set to Join Russell 3000® Index Effective June 28, 2024

    SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical nee

  • GlobeNewswire

    Atossa to Present at the Sidoti Small-Cap Investor Conference

    SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unm

  • GlobeNewswire

    Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

    SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model i